Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: Results from a Phase II trial (IFCT-1001 CHIVA)
| dc.rights.license | open | en_US |
| dc.contributor.author | WISLEZ, M. | |
| hal.structure.identifier | Immunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept] | |
| dc.contributor.author | DOMBLIDES, Charlotte | |
| dc.contributor.author | GREILLIER, L. | |
| dc.contributor.author | MAZIERES, J. | |
| dc.contributor.author | MONNET, I. | |
| dc.contributor.author | KIAKOUAMA-MALEKA, L. | |
| dc.contributor.author | QUANTIN, X. | |
| dc.contributor.author | SPANO, J.P. | |
| dc.contributor.author | RICORDEL, C. | |
| dc.contributor.author | FRAISSE, P. | |
| dc.contributor.author | JANICOT, H. | |
| dc.contributor.author | AUDIGIER-VALETTE, C. | |
| dc.contributor.author | AMOUR, E. | |
| dc.contributor.author | LANGLAIS, A. | |
| dc.contributor.author | RABBE, N. | |
| dc.contributor.author | MAKINSON, A. | |
| dc.contributor.author | CADRANEL, J. | |
| dc.contributor.author | LAURENT-PUIG, P. | |
| dc.contributor.author | LAVOLE, A. | |
| dc.contributor.author | BLONS, H. | |
| dc.date.accessioned | 2022-05-02T16:02:57Z | |
| dc.date.available | 2022-05-02T16:02:57Z | |
| dc.date.issued | 2021-05-13 | |
| dc.identifier.issn | 0169-5002 | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/139960 | |
| dc.description.abstractEn | Introduction: HIV is an exclusion criterion for most lung cancer (LC) trials, however LC is the most common non-AIDS-defined malignancy in people living with HIV (PLHIV), poorer prognosis than the general population. Circulating tumor DNA (ctDNA) was a prognostic marker in LC patients from the general population. This study assessed ctDNA's prognostic value in PLHIV from a dedicated phase II trial. Methods: Overall, 61 PLHIV with advanced non-squamous non-small-cell lung cancer (NSCLC) participated in the IFCT Phase II trial evaluating first-line four-cycle carboplatin (Ca) AUC5 pemetrexed (P) 500 mg/m2 induction therapy every 3 weeks, followed by P maintenance therapy. Blood samples collected before treatment were analyzed to detect ctDNA using ultra-deep targeted next-generation-sequencing (NGS). Results: Appropriate samples were available from 55 PLVIH and analyzed for ctDNA detection. Including 42 males (76.4 %), 52.9 years median age, 51 smokers (92.7 %), five with non-squamous NSCLC Stage III (9%), 50 Stage IV (91 %), and performance status (PS) 0?2. ctDNA was detected in 35 patients (64 %), 22 with high and 13 with low ctDNA levels. Overall, 77 % were positive for TP53, 29 % for KRAS, and 11 % for STK11 mutations, more than one alteration was detected in 43 % of samples. Multivariate analysis showed that positive ctDNA was significantly associated with shorter PFS (HR, 4.31, 95 %CI: 2.06?8.99, p < 0.0001), and shorter OS (HR, 3.52, 95 %CI: 1.72?7.19, p < 0.001). Moreover, OS was significantly longer for patients with low ctDNA levels at diagnosis as compared to high (p = 0.01). Conclusion: We show that ctDNA detection using ultra-deep NGS is an independent prognostic factor in PLHIV with advanced NSCLC. | |
| dc.language.iso | EN | en_US |
| dc.subject.en | Carboplatin | |
| dc.subject.en | Circulating tumor DNA | |
| dc.subject.en | HIV positivity | |
| dc.subject.en | Non-small-cell lung cancer | |
| dc.subject.en | Pemetrexed | |
| dc.title.en | Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: Results from a Phase II trial (IFCT-1001 CHIVA) | |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1016/j.lungcan.2021.05.013 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Immunologie | en_US |
| dc.identifier.pubmed | 34016488 | en_US |
| bordeaux.journal | Lung Cancer | en_US |
| bordeaux.page | 124-130 | en_US |
| bordeaux.volume | 157 | en_US |
| bordeaux.hal.laboratories | ImmunoConcEpT - UMR 5164 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | CNRS | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.export | false | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Lung%20Cancer&rft.date=2021-05-13&rft.volume=157&rft.spage=124-130&rft.epage=124-130&rft.eissn=0169-5002&rft.issn=0169-5002&rft.au=WISLEZ,%20M.&DOMBLIDES,%20Charlotte&GREILLIER,%20L.&MAZIERES,%20J.&MONNET,%20I.&rft.genre=article |
Fichier(s) constituant ce document
| Fichiers | Taille | Format | Vue |
|---|---|---|---|
|
Il n'y a pas de fichiers associés à ce document. |
|||